Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig Leonardi

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Journal of the American Academy of Dermatology|April 14, 2018
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasisClaus Zachariae, Kenneth Gordon, Alexandra B Kimball, et al.
Advances in Therapy|May 15, 2022
Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan<sup>®</sup> DatabasesCraig Leonardi, Baojin Zhu, William N Malatestinic, et al.
Journal of the American Academy of Dermatology|May 28, 2018
Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 studyCraig Leonardi, Catherine Maari, Sandra Philipp, et al.
Archives of Dermatology|December 22, 2010
Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trialCraig Leonardi, Richard G Langley, Kim Papp, et al.
Journal of Clinical Pharmacology|February 11, 2005
Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasisDeborah L Mortensen, Patricia A Walicke, Xiaolin Wang, et al.
Lancet (London, England)|January 10, 2006
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trialStephen Tyring, Alice Gottlieb, Kim Papp, et al.
Journal of Drugs in Dermatology : JDD|August 6, 2010
Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label studyCraig Leonardi, Bruce Strober, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|September 21, 2011
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trialsMark Lebwohl, Craig Leonardi, Christopher E M Griffiths, et al.
Plos One|June 16, 2011
Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritisKnut M Wittkowski, Craig Leonardi, Alice Gottlieb, et al.
The New England Journal of Medicine|March 30, 2012
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasisKim A Papp, Craig Leonardi, Alan Menter, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Journal of the American Academy of Dermatology|April 14, 2018
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasisClaus Zachariae, Kenneth Gordon, Alexandra B Kimball, et al.
Advances in Therapy|May 15, 2022
Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan<sup>®</sup> DatabasesCraig Leonardi, Baojin Zhu, William N Malatestinic, et al.
Journal of the American Academy of Dermatology|May 28, 2018
Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 studyCraig Leonardi, Catherine Maari, Sandra Philipp, et al.
Archives of Dermatology|December 22, 2010
Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trialCraig Leonardi, Richard G Langley, Kim Papp, et al.
Journal of Clinical Pharmacology|February 11, 2005
Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasisDeborah L Mortensen, Patricia A Walicke, Xiaolin Wang, et al.
Lancet (London, England)|January 10, 2006
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trialStephen Tyring, Alice Gottlieb, Kim Papp, et al.
Journal of Drugs in Dermatology : JDD|August 6, 2010
Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label studyCraig Leonardi, Bruce Strober, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|September 21, 2011
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trialsMark Lebwohl, Craig Leonardi, Christopher E M Griffiths, et al.
Plos One|June 16, 2011
Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritisKnut M Wittkowski, Craig Leonardi, Alice Gottlieb, et al.
The New England Journal of Medicine|March 30, 2012
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasisKim A Papp, Craig Leonardi, Alan Menter, et al.
Pageof 5